Cytotoxicity, Immunologic
"Cytotoxicity, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
| Descriptor ID |
D003602
|
| MeSH Number(s) |
G12.287
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cytotoxicity, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Cytotoxicity, Immunologic".
This graph shows the total number of publications written about "Cytotoxicity, Immunologic" by people in this website by year, and whether "Cytotoxicity, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 2 | 3 |
| 2001 | 1 | 2 | 3 |
| 2002 | 1 | 4 | 5 |
| 2003 | 1 | 4 | 5 |
| 2004 | 1 | 2 | 3 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 3 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 2 | 5 | 7 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 5 | 6 |
| 2012 | 1 | 3 | 4 |
| 2013 | 1 | 5 | 6 |
| 2014 | 0 | 5 | 5 |
| 2015 | 1 | 3 | 4 |
| 2016 | 0 | 3 | 3 |
| 2017 | 2 | 10 | 12 |
| 2018 | 0 | 2 | 2 |
| 2019 | 3 | 3 | 6 |
| 2020 | 0 | 3 | 3 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 5 | 5 |
| 2025 | 2 | 1 | 3 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytotoxicity, Immunologic" by people in Profiles.
-
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. Mol Ther. 2026 Apr 01; 34(4):2154-2174.
-
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. Sci Adv. 2025 Jan 10; 11(2):eadq8114.
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 06; 29(6):1379-1388.
-
Phenotypic and Functional Plasticity of CXCR6+ Peripheral Blood NK Cells. Front Immunol. 2021; 12:810080.
-
Distract NK cell killing: give them a fatty meal. Blood. 2020 12 24; 136(26):2969-2970.
-
Trichinella spiralis Calreticulin S-Domain Binds to Human Complement C1q to Interfere With C1q-Mediated Immune Functions. Front Immunol. 2020; 11:572326.
-
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.
-
Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatr Blood Cancer. 2019 10; 66(10):e27783.
-
IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol. 2018 10 01; 201(7):2141-2153.
-
A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models. Mol Ther. 2018 05 02; 26(5):1354-1365.